Scotch Plains, NJ, United States of America

Jing Su

USPTO Granted Patents = 23 (Patent Applications = 11)

EPO Patents = 10 (Patent Applications = 15)

Average Co-Inventor Count = 8.8

ph-index = 4

Forward Citations = 51(Granted Patents)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2002-2025

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12365656 - Oxazolidinone compounds and methods of use thereof as antibacterial agents (2025-07-22),

2. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),

3. 12180226 - Spirotricycle RIPK1 inhibitors and methods of uses thereof (2024-12-31),

4. 11932637 - Chromane amidine monobactam compounds for the treatment of bacterial infections (2024-03-19),

5. 11752128 - Benzimidazoles and indoles as taro inhibitors (2023-09-12),

6. 11738010 - Oxazolidinones as TarO inhibitors (2023-08-29),

7. 11141410 - Oxazolidinones as taro inhibitors (2021-10-12),

8. 11141403 - Benzimidazoles and indoles as taro inhibitors (2021-10-12),

9. 10947205 - Oxazolidinone compounds and methods of use thereof as antibacterial agents (2021-03-16),

10. 10752621 - Oxazolidinone compounds and methods of use thereof as antibacterial agents (2020-08-25),

11. 10144741 - Nargenicin compounds and uses thereof as antibacterial agents (2018-12-04),

12. 9944654 - Nargenicin compounds and uses thereof as antibacterial agents (2018-04-17),

13. 9839642 - Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors (2017-12-12),

14. 9708336 - Metallo-beta-lactamase inhibitors (2017-07-18),

15. 8569521 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2013-10-29),

Title: **Jing Su: Innovator in Pharmaceutical Patents**

Introduction:

Jing Su is a prominent inventor based in Scotch Plains, NJ, renowned for his contributions to the field of pharmaceuticals. With an impressive portfolio of 22 patents, his work focuses on the development of innovative compounds that target various diseases, particularly those involving complex biological pathways.

Latest Patents:

Jing Su's latest patents include groundbreaking innovations such as "1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors." This invention targets important kinases involved in the pathology of diseases like Parkinson's Disease, providing new avenues for treatment through pharmaceutical compositions. Another significant patent details "Spirotricycle RIPK1 inhibitors and methods of uses thereof." These compounds are designed to inhibit RIPK1, offering potential therapeutic options for diseases related to this kinase.

Career Highlights:

Throughout his career, Jing Su has worked with leading companies in the pharmaceutical industry. Notable among them are Merck Sharp & Dohme Corporation and Schering Corporation. His expertise has allowed him to navigate complex scientific challenges and contribute substantially to both technology and healthcare.

Collaborations:

Jing Su has collaborated with talented professionals in the field, including Mihir Mandal and Haiqun Tang. These partnerships have played a critical role in advancing his research and patent development, fostering innovation and scientific discovery.

Conclusion:

Jing Su has made significant strides in pharmaceutical innovations, particularly through his recent patents targeting critical kinases involved in various diseases. His collaborations and career experiences highlight the importance of teamwork in the development of novel therapeutic agents. As research continues, his contributions are likely to have a lasting impact on the field of medicine.

This text is generated by artificial intelligence and may not be accurate.